Credolegal Oy Research Reports

Title	Published	Price
Partnering and Business Trends in Transgenic Manufacturing By: Credolegal Oy Antibody companies have entered into contracts covering numerous antigen targets to use customers' core technology to generate and/or develop fully human antibodies. We expect that, for the foreseeable future, substantially all revenue models in the \| more... Search inside this report	11/17/2004	$325.00
Financial Modelling and Evaluation of Transgenic Manufacturing By: Credolegal Oy The use of financial models is critical for assessing the value of a transgenic manufacturing company (TM). These models must be tailored to reflect the unique features and risks associated with both the biotech and \| more... Search inside this report	11/17/2004	$200.00
Revenue Structure and Contract Models for Transgenic Manufacturing and Antibody Licensing By: Credolegal Oy Antibody companies have entered into contracts covering numerous antigen targets with the aim to use their customers' core technology to generate and/or develop fully human antibodies. We expect that, for the foreseeable future, substantially all \| more... Search inside this report	11/17/2004	$325.00
Plant Biotechnology - Evaluating Strategic Factors By: Credolegal Oy The key driving forces for the implementation of a new process technology are: a) Compelling need. The new process technology provides a solution to a specific and compelling product need. b) High-volume applications offer \| more... Search inside this report	11/17/2004	$150.00
Choosing the Proper Long-Term Manufacturing Strategy - System Comparison By: Credolegal Oy All antibodies currently on the market are manufactured by mammalian cell culture technology, and it is clearly the leading technology at the moment. However, there are a number of negative factors linked to this technology \| more... Search inside this report	11/17/2004	$225.00
Therapeutic Protein Industry, Value Mapping By: Credolegal Oy Many players in the pharmaceutical value-chain have announced that their long-term objective is to become a leader in the generation, development and commercialization of novel antibody-based biopharmaceutical products and to become fully integrated pharmaceutical companies. \| more... Search inside this report	11/17/2004	$112.00
Operating Tools for Transgenic Manufacturers By: Credolegal Oy Transgenic manufacturers are offering manufacturing capabilities to companies with proprietary therapeutic proteins such as monoclonal antibodies. However, these companies themselves often lack several functions required to achieve their commercial objectives, including in-house purification, scale-up, formulation \| more... Search inside this report	1/1/2004	$175.00
Title	Published	Price

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2008, All Rights Reserved, MarketResearch.com
12/1/2008 - 2